Analyst firms · Barclays · EMR
Barclays EMR price target and rating history
Emerson Electric Company (EMR) · Technology
Barclays rates Emerson Electric Company (EMR) Equal Weight with a $127 price target, as of its latest action on Aug 7, 2025. It has published 5 rating actions on EMR since July 2021, including 1 upgrade and 1 downgrade. Across 8 firms with a EMR price target in the last 12 months, the median target is $169.
- Current rating
- Equal Weight
- Price target
- $127
- Median target, all firms
- $169
- Actions on EMR
- 5
Barclays price target on EMR
Every Barclays rating on EMR
- Aug 7, 2025
- Mar 10, 2025
- Aug 28, 2023
- Jan 4, 2022
- Jul 8, 2021
How other firms rate EMR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| DA Davidson | Neutral | $145 | Jun 16, 2026 |
| Bernstein | Outperform | $175 | Jun 10, 2026 |
| Jefferies | Buy | $175 | Mar 31, 2026 |
| BMO Capital Markets | Market Perform | $150 | Mar 27, 2026 |
| Deutsche Bank | Hold | $170 | Feb 5, 2026 |
| Oppenheimer | Perform | Jan 27, 2026 | |
| TD Cowen | Hold | $150 | Jan 9, 2026 |
| UBS | Buy | $168 | Jan 5, 2026 |
| Evercore ISI | Outperform | $170 | Dec 15, 2025 |
Questions about Barclays and EMR
- What is Barclays's price target for EMR?
- Barclays's latest stated price target for Emerson Electric Company (EMR) is $127, from its action on Aug 7, 2025.
- What is Barclays's rating on EMR?
- Barclays rates EMR Equal Weight, a neutral rating, as of Aug 7, 2025.
- When did Barclays last change its view on EMR?
- On Aug 7, 2025, Barclays upgrades to Equal Weight from Underweight, price target $127.
- How does Barclays's EMR target compare with other analysts?
- Across 8 firms with a EMR price target in the last 12 months, the median target is $169.
More EMR rating histories
All Barclays ratingsEMR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.